ST Nuotai: Ipratropium Bromide Tablets Receive Drug Registration Certificate

robot
Abstract generation in progress

ST Nottai announcement: Recently, we received the “Drug Registration Certificate” for ipragliflozin tablets, duly approved and issued by the National Medical Products Administration (Certificate No.: 2026S00470). The drug name is ipragliflozin tablets; the dosage form is tablets; the specification is 50mg. The registration category is Chemical Drug Class 3, and the drug’s validity period is 18 months. The approval document number is Guo Yao Zhun Zi H20263399, valid until 2031-02-09. Both the marketing authorization holder and the manufacturer are Jiangsu Nottai Aocisino Biopharmaceutical Co., Ltd. The indication for ipragliflozin tablets is diabetic neuropathy. It is a reversible aldose reductase non-competitive inhibitor, with selective inhibition of aldose reductase.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin